Latest Headlines

  1. Algen Biotechnologies Announces Multi-Target Partnership To Advance AI-Powered Drug Discovery In Immunology With AstraZeneca 10/6/2025

    Algen Biotechnologies, a biotechnology company pioneering next-generation therapies using advanced CRISPR gene modulation and AI-driven drug discovery, today announced a multi-target partnership with AstraZeneca to accelerate the discovery of novel therapeutic targets in immunology.

  2. Monash University Establishes Boston-Based Hub To Expedite Drug Discoveries And Innovations 10/3/2025

    In response to its accelerated success in the research commercialisation arena, Monash University has today announced the establishment of the Monash Boston Hub located in Boston, USA.

  3. Elix, An AI Drug Discovery Company, And Tohoku University Enter Joint Research Agreement To Advance AI Drug Discovery 10/2/2025

    Elix, Inc. (CEO: Shinya Yuki / Headquarters: Tokyo; hereinafter “Elix”) and the Graduate School of Life Sciences at Tohoku University (Dean: Kouki Hikosaka / Headquarters: Miyagi; hereinafter “Tohoku University”) are pleased to announce the signing of a joint research agreement aimed at advancing drug discovery using AI technologies.

  4. XenoSTART And Minerva Imaging Expand Partnership To Deliver Integrated PDX-Radiopharmaceutical Drug Development Platform 10/2/2025

    The START Center for Cancer Research ("START"), its preclinical division XenoSTART, and Minerva Imaging today announced an expansion of their decade-long partnership to establish the industry's most comprehensive integrated platform for radiopharmaceutical drug development.

  5. QuantHealth Secures Strategic Investment From Sanofi Ventures To Accelerate AI-Driven Clinical Trials 10/1/2025

    QuantHealth, a pioneer in AI-driven clinical trial simulation, announced a strategic investment from Sanofi Ventures, the venture capital arm of global healthcare leader Sanofi. The investment will accelerate QuantHealth’s efforts to bring scalable, patient-level simulations and digital twin technologies to the forefront of drug development, bringing its total funds raised to $30M.

  6. Bristol Myers Squibb's Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation By U.S. FDA For The Treatment Of Alzheimer's Disease 10/1/2025

    Bristol Myers Squibb today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to BMS-986446, a potential best-in-class anti-microtubule binding region-tau (anti-MTBR-tau) antibody currently in Phase 2 development for the treatment of early Alzheimer’s disease.

  7. Pharming Group Announces U.S. FDA Acceptance And Priority Review Of Supplemental New Drug Application For Leniolisib In Children With APDS Aged 4 To 11 Years 10/1/2025

    Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) seeking approval for leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, as a treatment for children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency.

  8. Illumina Launches New Business To Accelerate Technology And Data-Driven Discovery 10/1/2025

    Illumina, Inc. (NASDAQ: ILMN) today announced the launch of BioInsight, a new business within Illumina, developed to meet industry demand for deeper biologic insights driven by the need of researchers and pharma companies to access and interpret ever larger-scale multiomic data.

  9. A New Analytical Tool To Optimize The Potency And Selectivity Of Drugs 9/30/2025

    Researchers at Baylor College of Medicine have developed a powerful new data analysis method named COOKIE-Pro (Covalent Occupancy Kinetic Enrichment via Proteomics) that provides a comprehensive, unbiased view of how a class of drugs, called covalent inhibitors, interacts with proteins throughout the cell.

  10. Disc Medicine Announces Submission Of New Drug Application (NDA) To US FDA For Accelerated Approval Of Bitopertin For Patients With Erythropoietic Protoporphyria (EPP) 9/30/2025

    Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for bitopertin for patients aged 12 years and older with erythropoietic protoporphyria (EPP), including X-linked protoporphyria (XLP).